青蒿琥酯抗宫颈癌作用机制的研究进展
Research Progress on the Mechanism of Artesunate against Cervical Cancer
DOI: 10.12677/acm.2025.15123520, PDF,   
作者: 李子章：承德医学院研究生学院，河北 承德；邢台人民医院妇二科，河北 邢台；张成果, 刘晓阳, 韩嘉瑶, 周 楠*：邢台人民医院妇二科，河北 邢台
关键词: 青蒿琥酯；宫颈肿瘤；作用机制；临床前景；Artesunate； Cervical Neoplasms； Mechanisms of Action； Clinical Prospects
摘要: 青蒿琥酯作为青蒿素的衍生物之一，因高效抗疟作用被广泛熟知，近年来其抗肿瘤潜力备受关注。宫颈癌作为全球女性高发恶性肿瘤，受耐药性、晚期转移及复发等问题影响，现有治疗效果有限。研究显示，该药物可通过多重机制发挥抗宫颈癌作用，包括诱导肿瘤细胞凋亡、触发铁死亡、抑制端粒酶活性、调节肿瘤免疫微环境、逆转放化疗耐药性，阻断肿瘤血管生成等，展现出显著的抗宫颈癌潜力。青蒿琥酯的多靶点作用特性为其老药新用、开发治疗药物或联合治疗方案提供了重要理论依据，有望为改善宫颈癌患者预后，尤其是难治性病例的治疗带来新突破。
Abstract: As one of the derivatives of artemisinin, artesunate is widely known for its potent antimalarial activity, and its antitumor potential has attracted considerable attention in recent years. Cervical cancer is a common malignant tumor among women worldwide, with limited efficacy of current treatments due to issues such as drug resistance, advanced metastasis, and recurrence. Studies have shown that artesunate exerts anti-cervical cancer effects through multiple mechanisms, including inducing tumor cell apoptosis, triggering ferroptosis, inhibiting telomerase activity, regulating the tumor immune microenvironment, reversing radioresistance and chemoresistance, and blocking tumor angiogenesis, etc. These findings demonstrate its significant anti-cervical cancer potential. The multi-targeted property of artesunate provides an important theoretical basis for its repurposing, development as a therapeutic agent, or formulation of combination therapy regimens. It is expected to bring new breakthroughs in improving the prognosis of cervical cancer patients, especially in the treatment of refractory cases.
文章引用：李子章, 张成果, 刘晓阳, 韩嘉瑶, 周楠. 青蒿琥酯抗宫颈癌作用机制的研究进展[J]. 临床医学进展, 2025, 15(12): 1202-1209. https://doi.org/10.12677/acm.2025.15123520

参考文献

[1] 王裕新, 潘凯枫, 李文庆. 2022全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2024, 10(3): 1-16.
[2] Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., et al. (2024) Cancer Incidence and Mortality in China, 2022. Journal of the National Cancer Center, 4, 47-53. [Google Scholar] [CrossRef] [PubMed]
[3] Huang, R., Liu, Z., Sun, T. and Zhu, L. (2024) Cervicovaginal Microbiome, High-Risk HPV Infection and Cervical Cancer: Mechanisms and Therapeutic Potential. Microbiological Research, 287, Article ID: 127857. [Google Scholar] [CrossRef] [PubMed]
[4] 蒋沅岐, 董玉洁, 周福军, 等. 青蒿素及其衍生物的研究进展[J]. 中草药, 2022, 53(2): 599-608.
[5] 张雨婷, Muhammad Shahbaz, 张蕊, 等. 青蒿琥酯联合用药及作用机制研究进展[J]. 中国实验方剂学杂志, 2024, 30(3): 290-298.
[6] An, J., Minie, M., Sasaki, T., Woodward, J.J. and Elkon, K.B. (2017) Antimalarial Drugs as Immune Modulators: New Mechanisms for Old Drugs. Annual Review of Medicine, 68, 317-330. [Google Scholar] [CrossRef] [PubMed]
[7] 封潇添, 马剑雄, 王岩, 等. 青蒿素及其衍生物治疗骨科相关疾病的研究进[J]. 中国中药杂志, 2024, 49(18): 4829-4840.
[8] 李林林, 张会敏, 宋健, 等. 青蒿琥酯的抗炎作用及机制研究进展[J]. 中国实验方剂学杂志, 2023, 29(12): 241-247.
[9] Strasser, A., Harris, A.W., Huang, D.C., Krammer, P.H. and Cory, S. (1995) Bcl-2 and Fas/APO-1 Regulate Distinct Pathways to Lymphocyte Apoptosis. The EMBO Journal, 14, 6136-6147. [Google Scholar] [CrossRef] [PubMed]
[10] Green, D.R. and Kroemer, G. (2004) The Pathophysiology of Mitochondrial Cell Death. Science, 305, 626-629. [Google Scholar] [CrossRef] [PubMed]
[11] Adams, J.M. and Cory, S. (1998) The Bcl-2 Protein Family: Arbiters of Cell Survival. Science, 281, 1322-1326. [Google Scholar] [CrossRef] [PubMed]
[12] Youle, R.J. and Strasser, A. (2008) The BCL-2 Protein Family: Opposing Activities That Mediate Cell Death. Nature Reviews Molecular Cell Biology, 9, 47-59. [Google Scholar] [CrossRef] [PubMed]
[13] Czabotar, P.E., Lessene, G., Strasser, A. and Adams, J.M. (2013) Control of Apoptosis by the BCL-2 Protein Family: Implications for Physiology and Therapy. Nature Reviews Molecular Cell Biology, 15, 49-63. [Google Scholar] [CrossRef] [PubMed]
[14] Kaloni, D., Diepstraten, S.T., Strasser, A. and Kelly, G.L. (2022) BCL-2 Protein Family: Attractive Targets for Cancer Therapy. Apoptosis, 28, 20-38. [Google Scholar] [CrossRef] [PubMed]
[15] Li, J., Cui, J., Li, Z., Fu, X., Li, J., Li, H., et al. (2020) ORP8 Induces Apoptosis by Releasing Cytochrome c from Mitochondria in Non-Small Cell Lung Cancer. Oncology Reports, 43, 1516-1524. [Google Scholar] [CrossRef] [PubMed]
[16] Zhang, Q., Li, X., He, C., Zhou, R., Wang, J. and Liu, L. (2024) Artesunate Promotes Cervical Cancer Cell Apoptosis by Regulating Bcl2 Family Molecules and Reducing the Mitochondrial Membrane Potential. Oncology Letters, 28, Article No. 315. [Google Scholar] [CrossRef] [PubMed]
[17] 夏洪平, 杨惠玲. p38 MAPK信号转导通路及其与细胞凋亡的关系[J]. 癌变. 畸变. 突变, 2006(3): 255-256.
[18] Wang, J., Zhang, B., Guo, Y., Li, G., Xie, Q., Zhu, B., et al. (2008) Artemisinin Inhibits Tumor Lymphangiogenesis by Suppression of Vascular Endothelial Growth Factor C. Pharmacology, 82, 148-155. [Google Scholar] [CrossRef] [PubMed]
[19] Hua, Y., Xianjie T, Jinghe L. (2017) Analysis of the Effects of Artemisinin Derivatives on Proliferation and Apoptosis of HeLa Cells in Cervical Cancer and Its Molecular Mechanism. Progress in Obstetrics and Gynecology, 26, 881-884.
[20] Wang, S. (2008) The Promise of Cancer Therapeutics Targeting the TNF-Related Apoptosis-Inducing Ligand and TRAIL Receptor Pathway. Oncogene, 27, 6207-6215. [Google Scholar] [CrossRef] [PubMed]
[21] Perez-Cruz, I., Cárcamo, J.M. and Golde, D.W. (2006) Caspase-8 Dependent TRAIL-Induced Apoptosis in Cancer Cell Lines Is Inhibited by Vitamin C and Catalase. Apoptosis, 12, 225-234. [Google Scholar] [CrossRef] [PubMed]
[22] Thanaketpaisarn, O., Waiwut, P., Sakurai, H., et al. (2011) Artesunate Enhances TRAIL-Induced Apoptosis in Human Cervical Carcinoma Cells through Inhibition of the NF-κB and PI3K/Akt Signaling Pathways. International Journal of Oncology, 39, 279-285.
[23] Shay, J.W. (2016) Role of Telomeres and Telomerase in Aging and Cancer. Cancer Discovery, 6, 584-593. [Google Scholar] [CrossRef] [PubMed]
[24] Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, P.L.C., et al. (1994) Specific Association of Human Telomerase Activity with Immortal Cells and Cancer. Science, 266, 2011-2015. [Google Scholar] [CrossRef] [PubMed]
[25] Mondal, A. and Chatterji, U. (2015) Artemisinin Represses Telomerase Subunits and Induces Apoptosis in HPV‐39 Infected Human Cervical Cancer Cells. Journal of Cellular Biochemistry, 116, 1968-1981. [Google Scholar] [CrossRef] [PubMed]
[26] Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., et al. (2012) Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell, 149, 1060-1072. [Google Scholar] [CrossRef] [PubMed]
[27] Li, J., Cao, F., Yin, H., Huang, Z., Lin, Z., Mao, N., et al. (2020) Ferroptosis: Past, Present and Future. Cell Death & Disease, 11, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[28] Sharma, G.N., Gupta, G. and Sharma, P. (2018) A Comprehensive Review of Free Radicals, Antioxidants, and Their Relationship with Human Ailments. Critical Reviews in Eukaryotic Gene Expression, 28, 139-154. [Google Scholar] [CrossRef] [PubMed]
[29] Disbrow, G.L., Baege, A.C., Kierpiec, K.A., Yuan, H., Centeno, J.A., Thibodeaux, C.A., et al. (2005) Dihydroartemisinin Is Cytotoxic to Papillomavirus-Expressing Epithelial Cells in Vitro and in Vivo. Cancer Research, 65, 10854-10861. [Google Scholar] [CrossRef] [PubMed]
[30] Siegel, E.M., Patel, N., Lu, B., Lee, J., Nyitray, A.G., Huang, X., et al. (2012) Circulating Biomarkers of Iron Storage and Clearance of Incident Human Papillomavirus Infection. Cancer Epidemiology, Biomarkers & Prevention, 21, 859-865. [Google Scholar] [CrossRef] [PubMed]
[31] Batty, K.T., Anh Thu, L.T., Davis, T.M.E., Ilett, K.F., Xuan Mai, T., Canh Hung, N., et al. (1998) A Pharmacokinetic and Pharmacodynamic Study of Intravenous vs Oral Artesunate in Uncomplicated Falciparum Malaria. British Journal of Clinical Pharmacology, 45, 123-129. [Google Scholar] [CrossRef] [PubMed]
[32] Zhang, C., Liu, X., Jin, S., Chen, Y. and Guo, R. (2022) Ferroptosis in Cancer Therapy: A Novel Approach to Reversing Drug Resistance. Molecular Cancer, 21, Article No. 47. [Google Scholar] [CrossRef] [PubMed]
[33] Shi, H., Xiong, L., Yan, G., Du, S., Liu, J. and Shi, Y. (2023) Susceptibility of Cervical Cancer to Dihydroartemisinin-Induced Ferritinophagy-Dependent Ferroptosis. Frontiers in Molecular Biosciences, 10, Article ID: 1156062. [Google Scholar] [CrossRef] [PubMed]
[34] Baratelli, F., Lin, Y., Zhu, L., Yang, S., Heuzé-Vourc’h, N., Zeng, G., et al. (2005) Prostaglandin E2 Induces foxp3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells. The Journal of Immunology, 175, 1483-1490. [Google Scholar] [CrossRef] [PubMed]
[35] Josefowicz, S.Z., Lu, L. and Rudensky, A.Y. (2012) Regulatory T Cells: Mechanisms of Differentiation and Function. Annual Review of Immunology, 30, 531-564. [Google Scholar] [CrossRef] [PubMed]
[36] Sales, K.J., Katz, A.A., Davis, M., Hinz, S., Soeters, R.P., Hofmeyr, M.D., et al. (2001) Cyclooxygenase-2 Expression and Prostaglandin E2 Synthesis Are Up-Regulated in Carcinomas of the Cervix: A Possible Autocrine/Paracrine Regulation of Neoplastic Cell Function via EP2/EP4 Receptors. The Journal of Clinical Endocrinology & Metabolism, 86, 2243-2249. [Google Scholar] [CrossRef] [PubMed]
[37] Zhang, L., Qian, H., Sha, M., Luan, Z., Lin, M., Yuan, D., et al. (2016) Downregulation of HOTAIR Expression Mediated Anti-Metastatic Effect of Artesunate on Cervical Cancer by Inhibiting COX-2 Expression. PLOS ONE, 11, e0164838. [Google Scholar] [CrossRef] [PubMed]
[38] Zhang, L.X., Liu, Z.N., Ye, J., Sha, M., Qian, H., Bu, X., et al. (2014) Artesunate Exerts an Anti‐Immunosuppressive Effect on Cervical Cancer by Inhibiting Pge2 Production and Foxp3 Expression. Cell Biology International, 38, 639-646. [Google Scholar] [CrossRef] [PubMed]
[39] Essmann, F., Engels, I.H., Totzke, G., Schulze-Osthoff, K. and Jänicke, R.U. (2004) Apoptosis Resistance of MCF-7 Breast Carcinoma Cells to Ionizing Radiation Is Independent of P53 and Cell Cycle Control but Caused by the Lack of Caspase-3 and a Caffeine-Inhibitable Event. Cancer Research, 64, 7065-7072. [Google Scholar] [CrossRef] [PubMed]
[40] Kawamoto, H., Koizumi, H. and Uchikoshi, T. (1997) Expression of the G2-M Checkpoint Regulators Cyclin B1 and cdc2 in Nonmalignant and Malignant Human Breast Lesions: Immunocytochemical and Quantitative Image Analyses. The American Journal of Pathology, 150, 15-23.
[41] 周媛媛, 封阳, 张旭光, 等. 青蒿琥酯对人宫颈癌HeLa和Siha细胞辐照后DNA损伤水平的影响[J]. 辐射研究与辐射工艺学报, 2011, 29(1): 33.
[42] Gong, X.M., Zhang, Q., Torossian, A., Cao, J. and Fu, S. (2012) Selective Radiosensitization of Human Cervical Cancer Cells and Normal Cells by Artemisinin through the Abrogation of Radiation-Induced G2 Block. International Journal of Gynecological Cancer, 22, 718-724. [Google Scholar] [CrossRef] [PubMed]
[43] 周媛媛. 青蒿琥酯对宫颈癌HeLa和Siha细胞裸鼠移植瘤放射增敏的实验研究[D]: [硕士学位论文]. 苏州: 苏州大学, 2011.
[44] 陈文佳, 毛霞, 张彦琼, 等. 青蒿琥酯对肿瘤放化疗增敏作用的研究现状分析和展望[J]. 中国中药杂志, 2019, 44(23): 5231-5239.
[45] Luo, J., Zhu, W., Tang, Y., Cao, H., Zhou, Y., Ji, R., et al. (2014) Artemisinin Derivative Artesunate Induces Radiosensitivity in Cervical Cancer Cells in Vitro and in Vivo. Radiation Oncology, 9, Article No. 84. [Google Scholar] [CrossRef] [PubMed]
[46] Niederreiter, M., Klein, J., Arndt, K., Werner, J. and Mayer, B. (2023) Anti-Cancer Effects of Artesunate in Human 3D Tumor Models of Different Complexity. International Journal of Molecular Sciences, 24, Article No. 7844. [Google Scholar] [CrossRef] [PubMed]
[47] 刘又彰. 青蒿琥酯对化疗耐药癌细胞裸鼠腮腺移植瘤c-Myc、ABCG2表达的影响[D]: [硕士学位论文]. 南宁: 广西医科大学, 2017.
[48] Chen, T.H., Huang, C.C., Yeh, K.T., et al. (2012) Human Papilloma Virus 16 E6 Oncoprotein Associated with P53 Inactivation in Colorectal Cancer. World Journal of Gastroenterology, 18, 4051-4058. [Google Scholar] [CrossRef] [PubMed]
[49] Helt, A.M. and Galloway, D.A. (2001) Destabilization of the Retinoblastoma Tumor Suppressor by Human Papillomavirus Type 16 E7 Is Not Sufficient to Overcome Cell Cycle Arrest in Human Keratinocytes. Journal of Virology, 75, 6737-6747. [Google Scholar] [CrossRef] [PubMed]
[50] Goodrich, S.K., Schlegel, C.R., Wang, G. and Belinson, J.L. (2014) Use of Artemisinin and Its Derivatives to Treat HPV-Infected/Transformed Cells and Cervical Cancer: A Review. Future Oncology, 10, 647-654. [Google Scholar] [CrossRef] [PubMed]
[51] Trimble, C.L., Levinson, K., Maldonado, L., Donovan, M.J., Clark, K.T., Fu, J., et al. (2020) A First-in-Human Proof-of-Concept Trial of Intravaginal Artesunate to Treat Cervical Intraepithelial Neoplasia 2/3 (CIN2/3). Gynecologic Oncology, 157, 188-194. [Google Scholar] [CrossRef] [PubMed]
[52] Michener, C.M., Ricci, S., AlHilli, M., Beffa, L., Debernardo, R., Waggoner, S.E., et al. (2023) Safety and Efficacy of Topical Artesunate for the Treatment of Vulvar Intraepithelial Neoplasia 2/3. Gynecologic Oncology, 178, 102-109. [Google Scholar] [CrossRef] [PubMed]
[53] Mungo, C., Sorgi, K., Misiko, B., et al. (2025) Phase I Study on the Pharmacokinetics of Intravaginal, Self-Administered Artesunate Vaginal Pessaries among Women in Kenya.
[54] Li, F. and Cui, J. (2015) Human Telomerase Reverse Transcriptase Regulates Vascular Endothelial Growth Factor Expression via Human Papillomavirus Oncogene E7 in HPV-18-Positive Cervical Cancer Cells. Medical Oncology, 32, Article No. 199. [Google Scholar] [CrossRef] [PubMed]

为你推荐